Imunon Reports $4.3 Million Net Loss in Q1 2026, Seeks Additional Capital

Imunon, Inc. reported a net loss of $4.3 million for the first quarter of 2026, a slight increase from the $4.1 million loss recorded in the same period of 2025. The company's total operating expenses rose to $4.3 million, compared to $4.1 million in the prior year, primarily driven by increased research and development costs associated with its clinical programs. Research and development expenses increased to $2.3 million from $2.2 million, reflecting ongoing investments in the OVATION clinical trials for its lead candidate, IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer.

As of March 31, 2026, Imunon had cash and cash equivalents totaling $4.8 million, a decrease from $8.8 million at the end of 2025. The company’s current liabilities also decreased to $4.2 million from $4.6 million, resulting in a net working capital of $2.0 million. The decline in cash reserves raises concerns about the company's ability to sustain operations, prompting management to express substantial doubt regarding its ability to continue as a going concern. The company plans to pursue additional capital through equity sales and strategic partnerships to fund its ongoing research and development activities.

Operationally, Imunon is advancing its clinical programs, particularly the OVATION 3 trial, which is currently enrolling patients. The company has opened seven sites for recruitment and is considering additional sites to expedite enrollment. The OVATION 2 trial has completed enrollment, and interim results have shown promising efficacy trends, including improved overall survival rates for patients treated with IMNN-001 in combination with standard chemotherapy. The company is also developing its PLACCINE DNA vaccine platform, with a focus on a COVID-19 booster vaccine, which has shown favorable safety and immunogenicity results in early trials.

In terms of strategic developments, Imunon has been actively seeking to enhance its financial position through various funding avenues, including its at-the-market (ATM) program. The company has issued approximately 3.2 million shares of common stock for net proceeds of about $14.9 million over the past year. However, the company acknowledges the challenges posed by current market conditions and the need for additional capital to support its ongoing operations and clinical trials. The outlook remains cautious, with management emphasizing the importance of securing funding to continue advancing its product candidates and achieving regulatory approvals.